The role of myeloid cells in the promotion of tumour angiogenesis

By Craig Murdoch, M. Muthana, S. Coffelt, C. Lewis. Nature Reviews. Cancer, 2008

1,710 citations recorded by the source corpus.

Subfields: Immunology, Molecular Biology, Oncology

View Paper: https://www.semanticscholar.org/paper/00da9e4806fa4e28301f5d54a7ba656b9dfbb1af

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Immunology

1. A. Mantovani
2. A. Sica
3. P. Allavena
4. D. Hanahan
5. J. Pollard
6. R. Weinberg
7. J. Joyce
8. C. Garlanda

In Molecular Biology

1. Zena Werb
2. D. Hanahan
3. R. Weinberg
4. J. Joyce
5. M. Egeblad
6. E. Nakasone
7. N. Ferrara
8. J. Pollard

In Oncology

1. R. Weinberg
2. D. Hanahan
3. A. Mantovani
4. Zena Werb
5. J. Pollard
6. P. Allavena
7. J. Joyce
8. A. Sica

Citations in the corpus

• Modes of resistance to anti-angiogenic therapy (2008, background): “Additional reviews, in this Focus on targeting angiogenesi”
• Cellular and Molecular Players in Adipose Tissue Inflammation in the Development of Obesity-induced Insulin Resistance (2013, neutral): “An example of these macrophages are the tumor-associated macrophages (TAMs) [48].”
• Microenvironmental regulation of metastasis (2009, background): “have all been shown to contribute to tumour angiogenesis through their production of growth factors, cytokines and proteases such as vascular endothelial growth factor A ( VEGFA ), PROK2 (also known as BV8) and matrix metalloproteinases (MMPs), respectively (reviewed in Ref”
• Tumor-Associated Macrophages as Major Players in the Tumor Microenvironment (2014, background): “Emerging evidence has suggested that the angiogenic switch in tumors depends on macrophage infiltration [63–65].”
• Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability. (2009, background): “It is well known that TAM accumulate in hypoxic regions of tumors and hypoxia triggers a proangiogenic program in these cells [66].”
• Angiopoietins in angiogenesis. (2013, neutral): “of angiogenic factors [26,27].”
• Targeting the tumour vasculature: insights from physiological angiogenesis (2010, background): “TAMs, which phenotypically resemble M2 macrophages, have been shown to accumulate in avascular, necrotic regions of advanced tumours and to express HIF1α and HIF2α, resulting in the transcription of numerous genes that promote revascularization, some of which include multiple pro-angiogenic factors ”
• Hallmarks of cancer: the next generation. (2011, positive): “…at the margins of tumors, tissue invasion, and to support the metastatic dissemination and seeding of cancer cells (Coffelt et al., 2010; Egeblad et al., 2010; Qian and Pollard, 2010; Mantovani, 2010; Joyce and Pollard, 2009; Mantovani et al., 2008; Murdoch et al., 2008; DePalma et al., 2007).”
• Macrophages, innate immunity and cancer: balance, tolerance, and diversity. (2010, background): “The presence of many areas of hypoxia is a hallmark feature of most forms of solid tumor [49] and TAM have been shown to accumulate in these areas where hypoxia promotes their pro-tumor phenotype [53].”
• Cellular Senescence: Aging, Cancer, and Injury. (2019, background): “Indeed, MDSCs produce MMPs that can support tumor cell invasion by directly promoting tumor angiogenesis and lymphangiogenesis (95, 237, 297, 354).”
• Immune evasion in cancer: Mechanistic basis and therapeutic strategies. (2015, background): “Myeloid cells, especially “myeloiderived suppressor cells” (MDSCs), modulated dendritic cells (DCs) nd alternatively-activated M1 and M2 macrophages create an nflammatory microenvironment and can also act as mediators of umor initiation, angiogenesis, and metastasis [23,24].”
• Myeloid-derived-suppressor cells as regulators of the immune system (2009, neutral): “However,as these non-immunological aspects of MDSC biology have recently been reviewed elsewher”